SlideShare ist ein Scribd-Unternehmen logo
1 von 53
Downloaden Sie, um offline zu lesen
The National Saudi Diabetic Guidelines for PHC
Quick Reference For
The National Saudi Diabetic Guidelines
For Primary Health care
Dr. Wedad Bardisi
ABFM. & SBFM
Chief editor
The National Saudi Diabetic Guidelines for PHC
Introduction
• The Challenge of Diabetes:
• Diabetes mellitus is a serious condition with potentially
devastating complications that affects all age groups
worldwide
• There is a huge increase in number of diabetics by 2030.
• Saudi Arabia the sixth of the Top Ten.
The National Saudi Diabetic Guidelines for PHC
Saudi Studies
• The different national studies for the epidemiology of diabetes
mellitus type 2, found that the incidence increased annually.
• A study at (Riyadh- 2011), found that, the overall crude
prevalence of DMT2 was 23.1%.
• Another study at (Jeddah-2011) estimated the prevalence
diabetes was 34.1% in males and 27.6% in females
The National Saudi Diabetic Guidelines for PHC
The Cost of diabetes
• Diabetes and its complications increase costs and service pressures
on Ministry of Health.
• A study Economic costs of diabetes in Saudi Arabia (2013) found
that People diagnosed with diabetes, on average, have medical
healthcare expenditures that are ten times higher ($3,686 vs. $380)
than what expenditures would be in the absence of diabetes.
• The impact of diabetes is significant not only for individuals but also
for their families and for society as a whole
The National Saudi Diabetic Guidelines for PHC
• The Saudi population can be regarded as a moderate risk population for
diabetes mellitus.
• The present management is unsatisfactory since those who are controlled
(HbA1C <7%) are only 20% of diabetic patients.
• It is suggested that steps must be taken to improve awareness of the disease
and to take measures to improve diabetes care
The National Saudi Diabetic Guidelines for PHC
Definition
Diabetes mellitus is a metabolic disorder characterized by the
presence of hyperglycemia due to defective insulin secretion,
defective insulin action or both
The National Saudi Diabetic Guidelines for PHC
Classification of Diabetes
Table. 1 Classification of diabetes
Type 1 diabetes* is diabetes that is primarily a result of pancreatic beta cell destruction and is prone to
ketoacidosis. This form includes cases due to an auto- immune process and those for which the etiology
of beta cell destruction is unknown.
Type 2 diabetes may range from predominant insulin resistance with relative insulin deficiency to a
predominant secretory defect with insulin resistance.
Gestational diabetes mellitus refers to glucose intolerance with onset or first recognition during
pregnancy.
Other specific types*
*Includes latent autoimmune diabetes in adults (LADA), and includes the small number of people with apparent
type 2 diabetes who appear to have immune-mediated loss of pancreatic beta cells
The National Saudi Diabetic Guidelines for PHC
Diagnosis of diabetes
1. HBA1C≥6.5%
OR
2. FPG ≥ 126 mg/dl (7.0 mmol/l)..
OR
2. Symptoms of hyperglycemia or hyperglycemic crisis, and a casual (random) plasma
glucose ≥ 200 mg/dl (11.1 mmol/l).
OR
3. 2-hours plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT.
*In the absence of unequivocal hyperglycemia, these criteria should be confirmed by repeated testing.
The National Saudi Diabetic Guidelines for PHC
Categories of increased risk for diabetes (prediabetes)
1- FPG 100 mg/dL (5.6 mmol/L) to 125 mg/d (6.9 mmol/L) (IFG)
OR
2- 2-h plasma glucose in the 75-gOGTT 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0
mmol/L)(IGT)
OR
3- A1C 5.7–6.4%
*For all three tests, risk is continuous, extending below the lower limit of the range
and becoming disproportionately greater at higher ends of the range.
The National Saudi Diabetic Guidelines for PHC
Risk factors for pre-diabetes and diabetes
• Overweight (BMI ≥25 kg/m2*) and have additional risk factors:
• Physical inactivity
• Family history
• High-risk race/ethnicity
• Women who delivered a baby weighing .9 lb or had GDM
• Hypertension
• HDL cholesterol level
• polycystic ovary syndrome
• A1C ≥5.7%, IGT, or IFG
• History of CVD
The National Saudi Diabetic Guidelines for PHC
Screening for Type 2 Diabetes
 Screening for type 2 diabetes using fasting plasma glucose (FPG)
should be performed every 3 years in individuals 40 years of age. or
in individuals at high risk using a risk calculator.
 Diabetes will be diagnosed if A1C is ≥6.5%.
 Testing with a 2-hour plasma glucose (2hPG) in a 75 g oral glucose
tolerance test (OGTT) should be undertaken in individuals with an
FPG of 5.6-6.9 mmol/L(100-125mh/dl) and/or an A1C of 5.7%-6.4%
in order to identify individuals with diabetes.
The National Saudi Diabetic Guidelines for PHC
Prevention/Delay of Diabetes
• Intensive and structured lifestyle modification that results in
loss of approximately 5% of initial body weight can reduce the
risk of progression from impaired glucose tolerance to type 2
diabetes by almost 60%.
• Progression from prediabetes to type 2 diabetes can also be
reduced by pharmacologic therapy with metformin (30%
reduction), acarbose ( 30% reduction).
The National Saudi Diabetic Guidelines for PHC
Monitoring Glycemic Control
• Glycated hemoglobin (A1C) is a valuable indicator of glycemic
control.
• Self monitoring of blood glucose (SMBG) results and
A1C,provides the best to assess glycemic control.
• The frequency of SMBG should be determined individually.
The National Saudi Diabetic Guidelines for PHC
Table 2: Factors that can affect A1C
Factor Increased A1C Decreased A1C Variable change in A1C
Erythropoiesis Iron deficiency
B12 deficiency
Decreased erythropoiesis
Use of erythropoietin, iron or B12
Reticulocytosis
Chronic liver disease
Altered hemoglobin
Fetal hemoglobin
Hemoglobinopathies
Methemoglobin
Genetic determinants
Altered glycation Alcoholism
Hemoglobinopathies
Chronic renal failure
Decreased erythrocyte pH
Ingestion of aspirin, vitamin C or
vitamin E
Increased erythrocyte pH
Erythrocyte destruction Increased erythrocyte lifespan:
Splenectomy
Decreased erythrocyte lifespan:
Chronic renal failure
Hemoglobinopathies
Splenomegaly
Rheumatoid arthritis
Antiretrovirals
Ribavirin
Dapsone
Assays Hyperbilirubinemia Carbamylated hemoglobin
Alcoholism
Large doses of aspirin
Chronic opiate use
Hypertriglyceridemia Hemoglobinopathies
The National Saudi Diabetic Guidelines for PHC
Targets for Glycemic Control
• A1C 7.0%
• FBS or Pre-prandial capillary plasma glucose
70–130mg/dL (3.9–7.2mmol/L)
• Peak postprandial capillary plasma glucose,
180 mg/dL*(10.0 mmol/L)
The National Saudi Diabetic Guidelines for PHC
Optimal glycemic control
• Individual patient considerations
• More or less stringent glycemic goals may be appropriate for
individual patients
• Postprandial glucose may be targeted if A1C goals are not met
despite reaching pre-prandial glucose goals
• *Postprandial glucose measurements should be made 1–2 h after
the beginning of the meal, generally peak levels in patients with
diabetes.
The National Saudi Diabetic Guidelines for PHC
Recommended Targets for Glycemic Control
The National Saudi Diabetic Guidelines for PHC
Pharmacologic Management of Type 2 Diabetes
• Lifestyle modification, including nutritional therapy and
physical activity, should continue to be emphasized while
pharmacotherapy is being used.
• Diabetic treatment must be dynamic.
The National Saudi Diabetic Guidelines for PHC
• A patient-centered approach should be used to guide choice of
pharmacological agents; considerations include efficacy, cost,
potential side effects, effects on weight, comorbidities,
hypoglycemia risk, and patient preferences.
• Due to the progressive nature of type 2 diabetes, insulin therapy is
eventually indicated for many patients with type 2 diabetes.
The National Saudi Diabetic Guidelines for PHC
Treatment Recommendations
• Metformin, is the preferred initial pharmacological agent for type 2
diabetes .
• In newly diagnosed type 2 diabetic patients with markedly
symptomatic and/or elevated blood glucose levels or A1C, consider
insulin therapy, with or without additional agents, from the outset.
• If noninsulin monotherapy at maximal tolerated dose does not
achieve or maintain the A1C target over 3–6 months, add a second
oral agent, a GLP-1 receptor agonist, or insulin.
The National Saudi Diabetic Guidelines for PHC
• A long acting insulin analogue is added to oral antihyperglycemic
agents.
• The addition of bedtime insulin to metformin therapy leads to less
weight gain than insulin plus a sulfonylurea or twice daily NPH
insulin .
• As type 2 diabetes progresses, doses of basal insulin (intermediate
acting or long acting analogues) will need increasing, pre-prandial
insulin (short acting or rapid acting analogues) may be required.
• A combination of oral antihyperglycemic agents and insulin often
effectively controls glucose levels.
The National Saudi Diabetic Guidelines for PHC
• DPP-4 inhibitors and GLP-1 receptor agonists have been shown
to be effective.
• As type 2 diabetes progresses, additional doses of basal
insulin may also be required.
• Insulin regimens based on basal or bolus insulin appear to be
equally effective and superior to biphasic insulin-based
regimens.
The National Saudi Diabetic Guidelines for PHC
Insulin Therapy
• When to initiate insulin therapy?
• Use a structured programme upon insulin initiation.
The National Saudi Diabetic Guidelines for PHC
Initiate Insulin Therapy
from a choice of a number of insulin types and regimens
• Begin with human NPH insulin injected at bed-time or twice
daily according to need.
• Consider, as an alternative, using a long-acting insulin
analogue (insulin detemir, insulin glargine).
The National Saudi Diabetic Guidelines for PHC
• Consider twice-daily pre-mixed (biphasic) human insulin
(particularly if HbA1c ≥ 9.0%).
• Consider pre-mixed preparations that include short-acting
insulin analogues, rather than pre-mixed preparations that
include short-acting human insulin preparations, in some
cases.
• Monitor persons on insulin frequently for any modifications.
The National Saudi Diabetic Guidelines for PHC
To lower post prandial blood glucose, use either of these
a)- Alph-glucosidase inhibitor.
b)- premixed insulin analogues.
c)- meglitinides.
d)- rapid-acting insulin analogues.
Important:
Counsel all diabetics about the recognition and prevention of
drug-induced hypoglycemia.
The National Saudi Diabetic Guidelines for PHC
The National Saudi Diabetic Guidelines for PHC
The National Saudi Diabetic Guidelines for PHC
The National Saudi Diabetic Guidelines for PHC
Anti-platelet therapy for people with diabetes
• The role of antiplatelet therapy in primary and secondary
prevention of cardiovascular disease in diabetics is variable,
and should be individualized.
The National Saudi Diabetic Guidelines for PHC
Recommendations
• Offer low-dose aspirin, (75-162) mg daily, to a person who is (male
aged >50 years / female aged >60 years) if blood pressure is below
145/90 mmHg.
• Offer low-dose aspirin, (75-162) mg daily, to a person who is (male
aged <50 years /female aged <60 years) and has significant other
cardiovascular risk factors if blood pressure is below 145/90 mmHg.
• Clopidogrel (75mg) should be used instead of aspirin only in those
with clear aspirin intolerance. (except in the context of acute
cardiovascular events and procedures).
• *Combination therapy with aspirin(75–162 mg/day) and clopidogrel
(75mg/day) is reasonable for up to a year after an acute coronary
syndrome.
The National Saudi Diabetic Guidelines for PHC
Identification of Individuals at High Risk of Coronary Events
• People with diabetes should be considered to have a high 10-year risk of
CAD events if 45 years and male, or 50 years and female.
• For the younger person (male <45 years or female <50 years) with diabetes,
the risk of developing CAD may be assessed from the evaluation of risk
factors for CAD (both classical and diabetes related).
• When assessing the need for pharmacologic measures to reduce risk in the
younger person with diabetes, it is important to consider his or her high
lifetime risk of developing CAD.
The National Saudi Diabetic Guidelines for PHC
Treatment of Hypertension
• In the prevention of diabetes-related complications, vascular protection is the
first priority, followed by control of hypertension in those whose blood
pressure (BP) levels remain above target, then nephroprotection for those with
proteinuria.
• People with diabetes and elevated BP should be aggressively treated to achieve
a target BP of <140/80 mm Hg to reduce the risk of both micro- and
macrovascular complications.
• Patients with diabetes should be treated to a diastolic blood pressure <80
mmHg
• Most people with diabetes will require more than one BP lowering medications
to achieve BP targets,
•
The National Saudi Diabetic Guidelines for PHC
JNC (American) classification OF Blood Pressure
Category Systolic Diastolic
Optimal <120 And <80
Normal <130 And /or <85
Prehypertension 130-139 And /or 85-89
Stage 1 (mild
hypertension)
140-159 And /or 90-99
Stage 2 (moderate
to severe
hypertension)
≥160 And /or ≥100
The National Saudi Diabetic Guidelines for PHC
Screening And Diagnosis
• Blood pressure should be measured at every routine visit.
• Patients found to have elevated blood pressure should have
blood pressure confirmed on a separate day.
The National Saudi Diabetic Guidelines for PHC
Goals
• The goal is 140 for systolic and 80 for diastolic.
• Some cases the systolic is recommended to be 130 for systolic
and 80 for diastolic.
The National Saudi Diabetic Guidelines for PHC
Treatment
• Life style therapy: low sodium , high potassium, DASH diet
Exercise.
• ACE inhibitors, or ARBS.
• If ACE inhibitors, ARBs, or diuretics are used, monitor serum
creatinine/estimated glomerular filtration rate (eGFR) and
serum potassium levels.
• Alpha-blockers are not recommended
The National Saudi Diabetic Guidelines for PHC
• A calcium channel blocker should be the first-line blood pressure-
lowering therapy for a woman who ay get pregnant.
• For diabetes and albuminuria an ACE inhibitor or an ARB is
recommended as initial therapy.
•
• If BP remains ≥ 140/80 mm Hg additional antihypertensive drugs
should be used to obtain target BP.
• For persons with diabetes and a normal urinary albumin excretion
rate, with no chronic kidney disease and with isolated systolic
hypertension, a long-acting DHP CCB is an initial choice.
The National Saudi Diabetic Guidelines for PHC
Dyslipidemia in Diabetes
• The primary treatment goal for people with diabetes is LDL-C
mmol/L(100mg/dl)HDL-c (≥50 mg/dl),TG ≤ 150 mg/dl)
• Achievement of the primary goal may require intensification of
lifestyle changes and/or statin therapy.
The National Saudi Diabetic Guidelines for PHC
Nephropathy
• Screening for CKD in diabetes should be conducted using a
random urine ACR and a serum creatinine converted into an
eGFR.
•
• Screening should commence at diagnosis of diabetes in
individuals with type 2 diabetes and yearly thereafter.
• A diagnosis of CKD should be made in patients with a random
urine ACR >2.0 mg/mmol and/or an eGFR<60 mL/min on at
least 2 of 3 samples over a 3-month period.
The National Saudi Diabetic Guidelines for PHC
• Suspect renal disease, when the albumin: creatinine ratio (ACR) is
raised and any of the following apply:
No retinopathy
High BP or resistant to treatment
had a documented normal ACR and develops heavy proteinuria (ACR
>100 mg/mmol)
Haematuria is present
Glomerular filtration rate has worsened rapidly
The person is systemically ill.
The National Saudi Diabetic Guidelines for PHC
• Adults with diabetes and persistent albuminuria (ACR >2. 0
mg/mmol in males, and females) should receive an ACE
inhibitor or an ARB to delay progression of CKD, even in the
absence of hypertension.
• For a person with an abnormal albumin: creatinine ratio,
maintain blood pressure below 130/80mmHg.
The National Saudi Diabetic Guidelines for PHC
Retinopathy
• Screening is important for early detection of treatable disease.
• Screening intervals for diabetic retinopathy vary according to
the individual’s age and type of diabetes.
• Tight glycemic, BP, and lipid control reduces the onset and
progression of sight-threatening diabetic retinopathy.
• Laser therapy reduces the risk of significant visual loss.
The National Saudi Diabetic Guidelines for PHC
Neuropathy
• Screening for distal symmetric polyneuropathy (DPN) starting
at diagnosis of type 2 diabetes and 5 years after the diagnosis
of type 1 diabetes and at least annually thereafter.
• Tests are, monofilament , vibration with 128 tuning fork, and
reflexes.
• Management of neuropathy include a trial of duloxetine,
gabapentin, or pregabalin.
The National Saudi Diabetic Guidelines for PHC
Erectile Dysfunction
• Erectile dysfunction (ED) affects approximately 34 to 45% of
men with diabetes.
• All adult men with diabetes should be regularly screened for ED
with a sexual function history.
• The current mainstays of therapy are phosphor diesterase type
5 inhibitors.
The National Saudi Diabetic Guidelines for PHC
Recommendations:
Medical Nutrition Therapy (MNT)
• Individuals who have prediabetes or diabetes should receive
individualized MNT as needed to achieve treatment goals,
preferably provided by a diabetic dietitian.
The National Saudi Diabetic Guidelines for PHC
Foot care
• For all patients with diabetes, perform an annual
comprehensive foot examination to identify risk factors
predictive of ulcers and amputations
– Inspection
– Assessment of foot pulses
– Test for loss of protective sensation: 10-g monofilament plus testing
any one of
• Vibration using 128-Hz tuning fork
• Pinprick sensation
• Ankle reflexes
• Vibration perception threshold
The National Saudi Diabetic Guidelines for PHC
Upper panel
• To perform the 10-g
monofilament test, place the
device perpendicular to the
skin, with pressure applied until
the monofilament buckles
• Hold in place for 1 second and
then release
Lower panel
• The monofilament test should
be performed at the highlighted
sites while the patient’s eyes
are closed
The National Saudi Diabetic Guidelines for PHC
Foot care
• Provide general foot self-care education
• Use multidisciplinary approach
– Individuals with foot ulcers, high-risk feet; especially prior ulcer or
amputation
• Refer patients to foot care specialists for ongoing preventive care,
life-long surveillance
– Smokers
– Loss of protective sensation or structural abnormalities
– History of prior lower-extremity complications
The National Saudi Diabetic Guidelines for PHC
• Initial screening for peripheral arterial disease (PAD)
– Include a history for claudication, assessment of pedal pulses
– Consider obtaining an ankle-brachial index (ABI); many patients with PAD
are asymptomatic
• Refer patients with significant claudication or a positive ABI for
further vascular assessment.
– Consider exercise, medications, surgical options.
The National Saudi Diabetic Guidelines for PHC
In Summary
• Diabetes mellitus is a chronic illness that requires continuing
medical care and ongoing patient self-management education
and support to prevent acute complications and to reduce the
risk of long-term complications.
• Diabetes care is complex and requires multifactorial risk
reduction strategies beyond glycemic control.
The National Saudi Diabetic Guidelines for PHC
References
1- the Saudi national diabetic guideline for primary care 2014
2-Diabetes mellitus in Saudi Arabia.
Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ, Khan NB, Al-Khadra A, Al-
Marzouki K, Nouh MS, Abdullah M, Attas O, Al-Shahid MS, Al-Mobeireek A. 2004.
3- Diabetes Impact in Saudi Health, Health minister,,Alruba,an et al - initial report 2008
4- Diabetes mellitus type 2 and other chronic non-communicable diseases in the central region, Saudi Arabia
(riyadh cohort 2): a decade of an epidemic Nasser M Al-Daghri12*, Omar S Al-Attas12, Majed S Alokail12, Khalid
M Alkharfy123, Mansour Yousef4, Shaun Louie Sabico1 and George P Chrousos Al-Daghri et al; licensee BioMed
Central Ltd 2011
5- Prevalence of diabetes mellitus in a Saudi community 2011
Khalid A. Alqurashi, Khalid S. Aljabri, and Samia A. Bokhari
6-IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030 Received 19 October 2011;
accepted 20 October 2011. published online 14 November 2011
The National Saudi Diabetic Guidelines for PHC
References
7-Economic costs of diabetes in Saudi Arabia Abdulkarim K. Alhowaish
Family Community Med. 2013 Jan-Apr; 20(1): 1–7.
8- Canadian journal of diabetes April 2013 - Volume 37 - Supplement 1
9--Canadian Clinical Practice guidelines 2013
Canadian journal of diabetes; April 2013 - Volume 37 - Supplement 1
10-American Diabetes Association2013
Standards of Medical Care in Diabetes
11- CG66 in NICE clinical guideline 87
September 2010 European Medicines.

Weitere ähnliche Inhalte

Was ist angesagt?

Management of Chronic Complications of Diabetes: Review of Current Guidelines...
Management of Chronic Complications of Diabetes: Review of Current Guidelines...Management of Chronic Complications of Diabetes: Review of Current Guidelines...
Management of Chronic Complications of Diabetes: Review of Current Guidelines...Bangabandhu Sheikh Mujib Medical University
 
New treatment for Diabetes Mellitus and Drugs to treat Hypoglycemia
New treatment for Diabetes Mellitus and Drugs to treat HypoglycemiaNew treatment for Diabetes Mellitus and Drugs to treat Hypoglycemia
New treatment for Diabetes Mellitus and Drugs to treat HypoglycemiaFarazaJaved
 
Highlights of ADA guidelines 2015 in Diabetes management
Highlights of ADA guidelines 2015 in Diabetes managementHighlights of ADA guidelines 2015 in Diabetes management
Highlights of ADA guidelines 2015 in Diabetes managementAhmed Elmoughazy
 
Optimising glycaemic control and body weight
Optimising glycaemic control and body weightOptimising glycaemic control and body weight
Optimising glycaemic control and body weightsimplyweight
 
Ueda2016 symposium -managing t2 dm with no compromise - khaled el hadidy
Ueda2016 symposium -managing t2 dm with no compromise -  khaled el hadidyUeda2016 symposium -managing t2 dm with no compromise -  khaled el hadidy
Ueda2016 symposium -managing t2 dm with no compromise - khaled el hadidyueda2015
 
Ueda 2016 5-pharmacological management of diabetes - lobna el toony
Ueda 2016 5-pharmacological management of diabetes  - lobna el toonyUeda 2016 5-pharmacological management of diabetes  - lobna el toony
Ueda 2016 5-pharmacological management of diabetes - lobna el toonyueda2015
 
Final control diabetes keep up to date 10 march 2016
Final control diabetes keep up to date 10 march 2016Final control diabetes keep up to date 10 march 2016
Final control diabetes keep up to date 10 march 2016alaa wafa
 
Role of early basal insulin initiation of t2 dm
Role of early basal insulin initiation of t2 dmRole of early basal insulin initiation of t2 dm
Role of early basal insulin initiation of t2 dmDr. Adel El Naggar
 
Anti diabetics and management of diabetic patients in maxillofacial surgery
Anti diabetics and management of diabetic patients in maxillofacial surgeryAnti diabetics and management of diabetic patients in maxillofacial surgery
Anti diabetics and management of diabetic patients in maxillofacial surgeryusha hathgain
 
ADA EASD Position Statement Management of Hyperglycemia in T2 DM April 2012
ADA EASD Position Statement  Management of Hyperglycemia in T2 DM April 2012ADA EASD Position Statement  Management of Hyperglycemia in T2 DM April 2012
ADA EASD Position Statement Management of Hyperglycemia in T2 DM April 2012Mahir Khalil Ibrahim Jallo
 
Beyond metformin dr clayton feb 22
Beyond metformin dr clayton feb 22Beyond metformin dr clayton feb 22
Beyond metformin dr clayton feb 22Ihsaan Peer
 

Was ist angesagt? (19)

Management of Chronic Complications of Diabetes: Review of Current Guidelines...
Management of Chronic Complications of Diabetes: Review of Current Guidelines...Management of Chronic Complications of Diabetes: Review of Current Guidelines...
Management of Chronic Complications of Diabetes: Review of Current Guidelines...
 
Non drug management of diabetesPPT
Non drug management of diabetesPPTNon drug management of diabetesPPT
Non drug management of diabetesPPT
 
New treatment for Diabetes Mellitus and Drugs to treat Hypoglycemia
New treatment for Diabetes Mellitus and Drugs to treat HypoglycemiaNew treatment for Diabetes Mellitus and Drugs to treat Hypoglycemia
New treatment for Diabetes Mellitus and Drugs to treat Hypoglycemia
 
Highlights of ADA guidelines 2015 in Diabetes management
Highlights of ADA guidelines 2015 in Diabetes managementHighlights of ADA guidelines 2015 in Diabetes management
Highlights of ADA guidelines 2015 in Diabetes management
 
Optimising glycaemic control and body weight
Optimising glycaemic control and body weightOptimising glycaemic control and body weight
Optimising glycaemic control and body weight
 
Ueda2016 symposium -managing t2 dm with no compromise - khaled el hadidy
Ueda2016 symposium -managing t2 dm with no compromise -  khaled el hadidyUeda2016 symposium -managing t2 dm with no compromise -  khaled el hadidy
Ueda2016 symposium -managing t2 dm with no compromise - khaled el hadidy
 
Updates of Diabetes Management by Dr Selim
Updates of Diabetes Management by Dr SelimUpdates of Diabetes Management by Dr Selim
Updates of Diabetes Management by Dr Selim
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Dm
DmDm
Dm
 
Diabetes
DiabetesDiabetes
Diabetes
 
Ueda 2016 5-pharmacological management of diabetes - lobna el toony
Ueda 2016 5-pharmacological management of diabetes  - lobna el toonyUeda 2016 5-pharmacological management of diabetes  - lobna el toony
Ueda 2016 5-pharmacological management of diabetes - lobna el toony
 
Final control diabetes keep up to date 10 march 2016
Final control diabetes keep up to date 10 march 2016Final control diabetes keep up to date 10 march 2016
Final control diabetes keep up to date 10 march 2016
 
Role of early basal insulin initiation of t2 dm
Role of early basal insulin initiation of t2 dmRole of early basal insulin initiation of t2 dm
Role of early basal insulin initiation of t2 dm
 
Diabetes care in hospital
Diabetes care in hospitalDiabetes care in hospital
Diabetes care in hospital
 
Anti diabetics and management of diabetic patients in maxillofacial surgery
Anti diabetics and management of diabetic patients in maxillofacial surgeryAnti diabetics and management of diabetic patients in maxillofacial surgery
Anti diabetics and management of diabetic patients in maxillofacial surgery
 
Dm audit
Dm auditDm audit
Dm audit
 
ADA EASD Position Statement Management of Hyperglycemia in T2 DM April 2012
ADA EASD Position Statement  Management of Hyperglycemia in T2 DM April 2012ADA EASD Position Statement  Management of Hyperglycemia in T2 DM April 2012
ADA EASD Position Statement Management of Hyperglycemia in T2 DM April 2012
 
Dm talk npt,tmo)
Dm talk npt,tmo)Dm talk npt,tmo)
Dm talk npt,tmo)
 
Beyond metformin dr clayton feb 22
Beyond metformin dr clayton feb 22Beyond metformin dr clayton feb 22
Beyond metformin dr clayton feb 22
 

Ähnlich wie DM Saudi Guidelines By DR. Wedad Bardisi.pptx

DR. Wedad Bardisi DM Saudi Guideline.pptx
DR. Wedad Bardisi DM Saudi Guideline.pptxDR. Wedad Bardisi DM Saudi Guideline.pptx
DR. Wedad Bardisi DM Saudi Guideline.pptxFayzaRayes
 
DR. Wedad Bardisi DM Saudi Guideline.pptx
DR. Wedad Bardisi DM Saudi Guideline.pptxDR. Wedad Bardisi DM Saudi Guideline.pptx
DR. Wedad Bardisi DM Saudi Guideline.pptxFayzaRayes
 
6th Upload on DPP4 Inhibitors
6th Upload on DPP4 Inhibitors6th Upload on DPP4 Inhibitors
6th Upload on DPP4 Inhibitorsdrmainuddin
 
Impact of patient counseling on diabetes mellitus patients in the territory c...
Impact of patient counseling on diabetes mellitus patients in the territory c...Impact of patient counseling on diabetes mellitus patients in the territory c...
Impact of patient counseling on diabetes mellitus patients in the territory c...SriramNagarajan17
 
General medicine update for every doctor
General medicine update for every doctorGeneral medicine update for every doctor
General medicine update for every doctorDINESH and SONALEE
 
Non-pharmacological Management of Diabetes Mellitus.pptx
Non-pharmacological Management of Diabetes Mellitus.pptxNon-pharmacological Management of Diabetes Mellitus.pptx
Non-pharmacological Management of Diabetes Mellitus.pptxSamson Ojedokun
 
Oral hypoglycemic agents with complications
Oral hypoglycemic agents with complicationsOral hypoglycemic agents with complications
Oral hypoglycemic agents with complicationschotatalha
 
Common pitfalls in diabetes management
Common pitfalls in diabetes managementCommon pitfalls in diabetes management
Common pitfalls in diabetes managementMohan Kubendra
 
...DIAGNOSIS OF DIABETES MELLITUS...
...DIAGNOSIS OF DIABETES MELLITUS......DIAGNOSIS OF DIABETES MELLITUS...
...DIAGNOSIS OF DIABETES MELLITUS...Dr.Subir Kumar
 
EPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptx
EPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptxEPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptx
EPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptxDrHarimuBargayary
 
KDIGO_Diabetes-in-CKD-Infographics-Set.pdf
KDIGO_Diabetes-in-CKD-Infographics-Set.pdfKDIGO_Diabetes-in-CKD-Infographics-Set.pdf
KDIGO_Diabetes-in-CKD-Infographics-Set.pdfMaiKhairy3
 
What is new in Diabetes
What is new in DiabetesWhat is new in Diabetes
What is new in Diabetesegyfellow
 
Diabetes lecture fall 2014
Diabetes lecture fall 2014Diabetes lecture fall 2014
Diabetes lecture fall 2014Alex Murray
 
Diabetes lecture fall 2014
Diabetes lecture fall 2014Diabetes lecture fall 2014
Diabetes lecture fall 2014Alex Murray
 
Dm and hypoglycemia2013
Dm and hypoglycemia2013Dm and hypoglycemia2013
Dm and hypoglycemia2013mohamed sandi
 

Ähnlich wie DM Saudi Guidelines By DR. Wedad Bardisi.pptx (20)

DR. Wedad Bardisi DM Saudi Guideline.pptx
DR. Wedad Bardisi DM Saudi Guideline.pptxDR. Wedad Bardisi DM Saudi Guideline.pptx
DR. Wedad Bardisi DM Saudi Guideline.pptx
 
DR. Wedad Bardisi DM Saudi Guideline.pptx
DR. Wedad Bardisi DM Saudi Guideline.pptxDR. Wedad Bardisi DM Saudi Guideline.pptx
DR. Wedad Bardisi DM Saudi Guideline.pptx
 
6th Upload on DPP4 Inhibitors
6th Upload on DPP4 Inhibitors6th Upload on DPP4 Inhibitors
6th Upload on DPP4 Inhibitors
 
Prediabetes a new appraisal
Prediabetes a new appraisal Prediabetes a new appraisal
Prediabetes a new appraisal
 
Impact of patient counseling on diabetes mellitus patients in the territory c...
Impact of patient counseling on diabetes mellitus patients in the territory c...Impact of patient counseling on diabetes mellitus patients in the territory c...
Impact of patient counseling on diabetes mellitus patients in the territory c...
 
DM PPT.pptx
DM PPT.pptxDM PPT.pptx
DM PPT.pptx
 
General medicine update for every doctor
General medicine update for every doctorGeneral medicine update for every doctor
General medicine update for every doctor
 
Non-pharmacological Management of Diabetes Mellitus.pptx
Non-pharmacological Management of Diabetes Mellitus.pptxNon-pharmacological Management of Diabetes Mellitus.pptx
Non-pharmacological Management of Diabetes Mellitus.pptx
 
Oral hypoglycemic agents with complications
Oral hypoglycemic agents with complicationsOral hypoglycemic agents with complications
Oral hypoglycemic agents with complications
 
Common pitfalls in diabetes management
Common pitfalls in diabetes managementCommon pitfalls in diabetes management
Common pitfalls in diabetes management
 
Diabetes basics.ppt
Diabetes basics.pptDiabetes basics.ppt
Diabetes basics.ppt
 
...DIAGNOSIS OF DIABETES MELLITUS...
...DIAGNOSIS OF DIABETES MELLITUS......DIAGNOSIS OF DIABETES MELLITUS...
...DIAGNOSIS OF DIABETES MELLITUS...
 
EPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptx
EPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptxEPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptx
EPIDEMIOLOGY AND RECENT ADVANCES IN DIABETES & OBESITY - HARIMU.pptx
 
Classification &amp; Diagnosis Of Diabetes
Classification &amp; Diagnosis Of DiabetesClassification &amp; Diagnosis Of Diabetes
Classification &amp; Diagnosis Of Diabetes
 
KDIGO_Diabetes-in-CKD-Infographics-Set.pdf
KDIGO_Diabetes-in-CKD-Infographics-Set.pdfKDIGO_Diabetes-in-CKD-Infographics-Set.pdf
KDIGO_Diabetes-in-CKD-Infographics-Set.pdf
 
What is new in Diabetes
What is new in DiabetesWhat is new in Diabetes
What is new in Diabetes
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Diabetes lecture fall 2014
Diabetes lecture fall 2014Diabetes lecture fall 2014
Diabetes lecture fall 2014
 
Diabetes lecture fall 2014
Diabetes lecture fall 2014Diabetes lecture fall 2014
Diabetes lecture fall 2014
 
Dm and hypoglycemia2013
Dm and hypoglycemia2013Dm and hypoglycemia2013
Dm and hypoglycemia2013
 

Mehr von FayzaRayes

Steps of Smoking Cessation Badr Bin Himd.pptx
Steps of Smoking Cessation Badr Bin Himd.pptxSteps of Smoking Cessation Badr Bin Himd.pptx
Steps of Smoking Cessation Badr Bin Himd.pptxFayzaRayes
 
Introduction FM2 [2014]
Introduction FM2 [2014]Introduction FM2 [2014]
Introduction FM2 [2014]FayzaRayes
 
Introduction FM3 [2014]
Introduction FM3 [2014]Introduction FM3 [2014]
Introduction FM3 [2014]FayzaRayes
 
Illness Behavior IMC الأهلة التفاعل مع المرض 2013
Illness Behavior IMC الأهلة التفاعل مع المرض 2013Illness Behavior IMC الأهلة التفاعل مع المرض 2013
Illness Behavior IMC الأهلة التفاعل مع المرض 2013FayzaRayes
 
MCQs Techniques
MCQs TechniquesMCQs Techniques
MCQs TechniquesFayzaRayes
 
Introduction FM2
Introduction FM2Introduction FM2
Introduction FM2FayzaRayes
 
Cholesterol Myth and Truth
Cholesterol Myth and TruthCholesterol Myth and Truth
Cholesterol Myth and TruthFayzaRayes
 
Smoking Counseling
Smoking CounselingSmoking Counseling
Smoking CounselingFayzaRayes
 
Very Special Pictures
Very Special PicturesVery Special Pictures
Very Special PicturesFayzaRayes
 
Migraine and tension headache
Migraine and tension headacheMigraine and tension headache
Migraine and tension headacheFayzaRayes
 
Health Education
Health EducationHealth Education
Health EducationFayzaRayes
 
Health education
Health educationHealth education
Health educationFayzaRayes
 
Applying consultation skills
Applying consultation skillsApplying consultation skills
Applying consultation skillsFayzaRayes
 
Dermatology approach
Dermatology approachDermatology approach
Dermatology approachFayzaRayes
 
Dermatolody quizzes
Dermatolody quizzesDermatolody quizzes
Dermatolody quizzesFayzaRayes
 
Consultation models
Consultation modelsConsultation models
Consultation modelsFayzaRayes
 

Mehr von FayzaRayes (19)

Steps of Smoking Cessation Badr Bin Himd.pptx
Steps of Smoking Cessation Badr Bin Himd.pptxSteps of Smoking Cessation Badr Bin Himd.pptx
Steps of Smoking Cessation Badr Bin Himd.pptx
 
Introduction FM2 [2014]
Introduction FM2 [2014]Introduction FM2 [2014]
Introduction FM2 [2014]
 
Introduction FM3 [2014]
Introduction FM3 [2014]Introduction FM3 [2014]
Introduction FM3 [2014]
 
Illness Behavior IMC الأهلة التفاعل مع المرض 2013
Illness Behavior IMC الأهلة التفاعل مع المرض 2013Illness Behavior IMC الأهلة التفاعل مع المرض 2013
Illness Behavior IMC الأهلة التفاعل مع المرض 2013
 
MCQs Techniques
MCQs TechniquesMCQs Techniques
MCQs Techniques
 
Joint X-Ray
Joint X-RayJoint X-Ray
Joint X-Ray
 
Urin Analysis
Urin AnalysisUrin Analysis
Urin Analysis
 
Introduction FM2
Introduction FM2Introduction FM2
Introduction FM2
 
Cholesterol Myth and Truth
Cholesterol Myth and TruthCholesterol Myth and Truth
Cholesterol Myth and Truth
 
Smoking Counseling
Smoking CounselingSmoking Counseling
Smoking Counseling
 
Very Special Pictures
Very Special PicturesVery Special Pictures
Very Special Pictures
 
Cartoons
CartoonsCartoons
Cartoons
 
Migraine and tension headache
Migraine and tension headacheMigraine and tension headache
Migraine and tension headache
 
Health Education
Health EducationHealth Education
Health Education
 
Health education
Health educationHealth education
Health education
 
Applying consultation skills
Applying consultation skillsApplying consultation skills
Applying consultation skills
 
Dermatology approach
Dermatology approachDermatology approach
Dermatology approach
 
Dermatolody quizzes
Dermatolody quizzesDermatolody quizzes
Dermatolody quizzes
 
Consultation models
Consultation modelsConsultation models
Consultation models
 

DM Saudi Guidelines By DR. Wedad Bardisi.pptx

  • 1. The National Saudi Diabetic Guidelines for PHC Quick Reference For The National Saudi Diabetic Guidelines For Primary Health care Dr. Wedad Bardisi ABFM. & SBFM Chief editor
  • 2. The National Saudi Diabetic Guidelines for PHC Introduction • The Challenge of Diabetes: • Diabetes mellitus is a serious condition with potentially devastating complications that affects all age groups worldwide • There is a huge increase in number of diabetics by 2030. • Saudi Arabia the sixth of the Top Ten.
  • 3. The National Saudi Diabetic Guidelines for PHC Saudi Studies • The different national studies for the epidemiology of diabetes mellitus type 2, found that the incidence increased annually. • A study at (Riyadh- 2011), found that, the overall crude prevalence of DMT2 was 23.1%. • Another study at (Jeddah-2011) estimated the prevalence diabetes was 34.1% in males and 27.6% in females
  • 4. The National Saudi Diabetic Guidelines for PHC The Cost of diabetes • Diabetes and its complications increase costs and service pressures on Ministry of Health. • A study Economic costs of diabetes in Saudi Arabia (2013) found that People diagnosed with diabetes, on average, have medical healthcare expenditures that are ten times higher ($3,686 vs. $380) than what expenditures would be in the absence of diabetes. • The impact of diabetes is significant not only for individuals but also for their families and for society as a whole
  • 5. The National Saudi Diabetic Guidelines for PHC • The Saudi population can be regarded as a moderate risk population for diabetes mellitus. • The present management is unsatisfactory since those who are controlled (HbA1C <7%) are only 20% of diabetic patients. • It is suggested that steps must be taken to improve awareness of the disease and to take measures to improve diabetes care
  • 6. The National Saudi Diabetic Guidelines for PHC Definition Diabetes mellitus is a metabolic disorder characterized by the presence of hyperglycemia due to defective insulin secretion, defective insulin action or both
  • 7. The National Saudi Diabetic Guidelines for PHC Classification of Diabetes Table. 1 Classification of diabetes Type 1 diabetes* is diabetes that is primarily a result of pancreatic beta cell destruction and is prone to ketoacidosis. This form includes cases due to an auto- immune process and those for which the etiology of beta cell destruction is unknown. Type 2 diabetes may range from predominant insulin resistance with relative insulin deficiency to a predominant secretory defect with insulin resistance. Gestational diabetes mellitus refers to glucose intolerance with onset or first recognition during pregnancy. Other specific types* *Includes latent autoimmune diabetes in adults (LADA), and includes the small number of people with apparent type 2 diabetes who appear to have immune-mediated loss of pancreatic beta cells
  • 8. The National Saudi Diabetic Guidelines for PHC Diagnosis of diabetes 1. HBA1C≥6.5% OR 2. FPG ≥ 126 mg/dl (7.0 mmol/l).. OR 2. Symptoms of hyperglycemia or hyperglycemic crisis, and a casual (random) plasma glucose ≥ 200 mg/dl (11.1 mmol/l). OR 3. 2-hours plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. *In the absence of unequivocal hyperglycemia, these criteria should be confirmed by repeated testing.
  • 9. The National Saudi Diabetic Guidelines for PHC Categories of increased risk for diabetes (prediabetes) 1- FPG 100 mg/dL (5.6 mmol/L) to 125 mg/d (6.9 mmol/L) (IFG) OR 2- 2-h plasma glucose in the 75-gOGTT 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L)(IGT) OR 3- A1C 5.7–6.4% *For all three tests, risk is continuous, extending below the lower limit of the range and becoming disproportionately greater at higher ends of the range.
  • 10. The National Saudi Diabetic Guidelines for PHC Risk factors for pre-diabetes and diabetes • Overweight (BMI ≥25 kg/m2*) and have additional risk factors: • Physical inactivity • Family history • High-risk race/ethnicity • Women who delivered a baby weighing .9 lb or had GDM • Hypertension • HDL cholesterol level • polycystic ovary syndrome • A1C ≥5.7%, IGT, or IFG • History of CVD
  • 11. The National Saudi Diabetic Guidelines for PHC Screening for Type 2 Diabetes  Screening for type 2 diabetes using fasting plasma glucose (FPG) should be performed every 3 years in individuals 40 years of age. or in individuals at high risk using a risk calculator.  Diabetes will be diagnosed if A1C is ≥6.5%.  Testing with a 2-hour plasma glucose (2hPG) in a 75 g oral glucose tolerance test (OGTT) should be undertaken in individuals with an FPG of 5.6-6.9 mmol/L(100-125mh/dl) and/or an A1C of 5.7%-6.4% in order to identify individuals with diabetes.
  • 12. The National Saudi Diabetic Guidelines for PHC Prevention/Delay of Diabetes • Intensive and structured lifestyle modification that results in loss of approximately 5% of initial body weight can reduce the risk of progression from impaired glucose tolerance to type 2 diabetes by almost 60%. • Progression from prediabetes to type 2 diabetes can also be reduced by pharmacologic therapy with metformin (30% reduction), acarbose ( 30% reduction).
  • 13. The National Saudi Diabetic Guidelines for PHC Monitoring Glycemic Control • Glycated hemoglobin (A1C) is a valuable indicator of glycemic control. • Self monitoring of blood glucose (SMBG) results and A1C,provides the best to assess glycemic control. • The frequency of SMBG should be determined individually.
  • 14. The National Saudi Diabetic Guidelines for PHC Table 2: Factors that can affect A1C Factor Increased A1C Decreased A1C Variable change in A1C Erythropoiesis Iron deficiency B12 deficiency Decreased erythropoiesis Use of erythropoietin, iron or B12 Reticulocytosis Chronic liver disease Altered hemoglobin Fetal hemoglobin Hemoglobinopathies Methemoglobin Genetic determinants Altered glycation Alcoholism Hemoglobinopathies Chronic renal failure Decreased erythrocyte pH Ingestion of aspirin, vitamin C or vitamin E Increased erythrocyte pH Erythrocyte destruction Increased erythrocyte lifespan: Splenectomy Decreased erythrocyte lifespan: Chronic renal failure Hemoglobinopathies Splenomegaly Rheumatoid arthritis Antiretrovirals Ribavirin Dapsone Assays Hyperbilirubinemia Carbamylated hemoglobin Alcoholism Large doses of aspirin Chronic opiate use Hypertriglyceridemia Hemoglobinopathies
  • 15. The National Saudi Diabetic Guidelines for PHC Targets for Glycemic Control • A1C 7.0% • FBS or Pre-prandial capillary plasma glucose 70–130mg/dL (3.9–7.2mmol/L) • Peak postprandial capillary plasma glucose, 180 mg/dL*(10.0 mmol/L)
  • 16. The National Saudi Diabetic Guidelines for PHC Optimal glycemic control • Individual patient considerations • More or less stringent glycemic goals may be appropriate for individual patients • Postprandial glucose may be targeted if A1C goals are not met despite reaching pre-prandial glucose goals • *Postprandial glucose measurements should be made 1–2 h after the beginning of the meal, generally peak levels in patients with diabetes.
  • 17. The National Saudi Diabetic Guidelines for PHC Recommended Targets for Glycemic Control
  • 18. The National Saudi Diabetic Guidelines for PHC Pharmacologic Management of Type 2 Diabetes • Lifestyle modification, including nutritional therapy and physical activity, should continue to be emphasized while pharmacotherapy is being used. • Diabetic treatment must be dynamic.
  • 19. The National Saudi Diabetic Guidelines for PHC • A patient-centered approach should be used to guide choice of pharmacological agents; considerations include efficacy, cost, potential side effects, effects on weight, comorbidities, hypoglycemia risk, and patient preferences. • Due to the progressive nature of type 2 diabetes, insulin therapy is eventually indicated for many patients with type 2 diabetes.
  • 20. The National Saudi Diabetic Guidelines for PHC Treatment Recommendations • Metformin, is the preferred initial pharmacological agent for type 2 diabetes . • In newly diagnosed type 2 diabetic patients with markedly symptomatic and/or elevated blood glucose levels or A1C, consider insulin therapy, with or without additional agents, from the outset. • If noninsulin monotherapy at maximal tolerated dose does not achieve or maintain the A1C target over 3–6 months, add a second oral agent, a GLP-1 receptor agonist, or insulin.
  • 21. The National Saudi Diabetic Guidelines for PHC • A long acting insulin analogue is added to oral antihyperglycemic agents. • The addition of bedtime insulin to metformin therapy leads to less weight gain than insulin plus a sulfonylurea or twice daily NPH insulin . • As type 2 diabetes progresses, doses of basal insulin (intermediate acting or long acting analogues) will need increasing, pre-prandial insulin (short acting or rapid acting analogues) may be required. • A combination of oral antihyperglycemic agents and insulin often effectively controls glucose levels.
  • 22. The National Saudi Diabetic Guidelines for PHC • DPP-4 inhibitors and GLP-1 receptor agonists have been shown to be effective. • As type 2 diabetes progresses, additional doses of basal insulin may also be required. • Insulin regimens based on basal or bolus insulin appear to be equally effective and superior to biphasic insulin-based regimens.
  • 23. The National Saudi Diabetic Guidelines for PHC Insulin Therapy • When to initiate insulin therapy? • Use a structured programme upon insulin initiation.
  • 24. The National Saudi Diabetic Guidelines for PHC Initiate Insulin Therapy from a choice of a number of insulin types and regimens • Begin with human NPH insulin injected at bed-time or twice daily according to need. • Consider, as an alternative, using a long-acting insulin analogue (insulin detemir, insulin glargine).
  • 25. The National Saudi Diabetic Guidelines for PHC • Consider twice-daily pre-mixed (biphasic) human insulin (particularly if HbA1c ≥ 9.0%). • Consider pre-mixed preparations that include short-acting insulin analogues, rather than pre-mixed preparations that include short-acting human insulin preparations, in some cases. • Monitor persons on insulin frequently for any modifications.
  • 26. The National Saudi Diabetic Guidelines for PHC To lower post prandial blood glucose, use either of these a)- Alph-glucosidase inhibitor. b)- premixed insulin analogues. c)- meglitinides. d)- rapid-acting insulin analogues. Important: Counsel all diabetics about the recognition and prevention of drug-induced hypoglycemia.
  • 27. The National Saudi Diabetic Guidelines for PHC
  • 28. The National Saudi Diabetic Guidelines for PHC
  • 29. The National Saudi Diabetic Guidelines for PHC
  • 30. The National Saudi Diabetic Guidelines for PHC Anti-platelet therapy for people with diabetes • The role of antiplatelet therapy in primary and secondary prevention of cardiovascular disease in diabetics is variable, and should be individualized.
  • 31. The National Saudi Diabetic Guidelines for PHC Recommendations • Offer low-dose aspirin, (75-162) mg daily, to a person who is (male aged >50 years / female aged >60 years) if blood pressure is below 145/90 mmHg. • Offer low-dose aspirin, (75-162) mg daily, to a person who is (male aged <50 years /female aged <60 years) and has significant other cardiovascular risk factors if blood pressure is below 145/90 mmHg. • Clopidogrel (75mg) should be used instead of aspirin only in those with clear aspirin intolerance. (except in the context of acute cardiovascular events and procedures). • *Combination therapy with aspirin(75–162 mg/day) and clopidogrel (75mg/day) is reasonable for up to a year after an acute coronary syndrome.
  • 32. The National Saudi Diabetic Guidelines for PHC Identification of Individuals at High Risk of Coronary Events • People with diabetes should be considered to have a high 10-year risk of CAD events if 45 years and male, or 50 years and female. • For the younger person (male <45 years or female <50 years) with diabetes, the risk of developing CAD may be assessed from the evaluation of risk factors for CAD (both classical and diabetes related). • When assessing the need for pharmacologic measures to reduce risk in the younger person with diabetes, it is important to consider his or her high lifetime risk of developing CAD.
  • 33. The National Saudi Diabetic Guidelines for PHC Treatment of Hypertension • In the prevention of diabetes-related complications, vascular protection is the first priority, followed by control of hypertension in those whose blood pressure (BP) levels remain above target, then nephroprotection for those with proteinuria. • People with diabetes and elevated BP should be aggressively treated to achieve a target BP of <140/80 mm Hg to reduce the risk of both micro- and macrovascular complications. • Patients with diabetes should be treated to a diastolic blood pressure <80 mmHg • Most people with diabetes will require more than one BP lowering medications to achieve BP targets, •
  • 34. The National Saudi Diabetic Guidelines for PHC JNC (American) classification OF Blood Pressure Category Systolic Diastolic Optimal <120 And <80 Normal <130 And /or <85 Prehypertension 130-139 And /or 85-89 Stage 1 (mild hypertension) 140-159 And /or 90-99 Stage 2 (moderate to severe hypertension) ≥160 And /or ≥100
  • 35. The National Saudi Diabetic Guidelines for PHC Screening And Diagnosis • Blood pressure should be measured at every routine visit. • Patients found to have elevated blood pressure should have blood pressure confirmed on a separate day.
  • 36. The National Saudi Diabetic Guidelines for PHC Goals • The goal is 140 for systolic and 80 for diastolic. • Some cases the systolic is recommended to be 130 for systolic and 80 for diastolic.
  • 37. The National Saudi Diabetic Guidelines for PHC Treatment • Life style therapy: low sodium , high potassium, DASH diet Exercise. • ACE inhibitors, or ARBS. • If ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine/estimated glomerular filtration rate (eGFR) and serum potassium levels. • Alpha-blockers are not recommended
  • 38. The National Saudi Diabetic Guidelines for PHC • A calcium channel blocker should be the first-line blood pressure- lowering therapy for a woman who ay get pregnant. • For diabetes and albuminuria an ACE inhibitor or an ARB is recommended as initial therapy. • • If BP remains ≥ 140/80 mm Hg additional antihypertensive drugs should be used to obtain target BP. • For persons with diabetes and a normal urinary albumin excretion rate, with no chronic kidney disease and with isolated systolic hypertension, a long-acting DHP CCB is an initial choice.
  • 39. The National Saudi Diabetic Guidelines for PHC Dyslipidemia in Diabetes • The primary treatment goal for people with diabetes is LDL-C mmol/L(100mg/dl)HDL-c (≥50 mg/dl),TG ≤ 150 mg/dl) • Achievement of the primary goal may require intensification of lifestyle changes and/or statin therapy.
  • 40. The National Saudi Diabetic Guidelines for PHC Nephropathy • Screening for CKD in diabetes should be conducted using a random urine ACR and a serum creatinine converted into an eGFR. • • Screening should commence at diagnosis of diabetes in individuals with type 2 diabetes and yearly thereafter. • A diagnosis of CKD should be made in patients with a random urine ACR >2.0 mg/mmol and/or an eGFR<60 mL/min on at least 2 of 3 samples over a 3-month period.
  • 41. The National Saudi Diabetic Guidelines for PHC • Suspect renal disease, when the albumin: creatinine ratio (ACR) is raised and any of the following apply: No retinopathy High BP or resistant to treatment had a documented normal ACR and develops heavy proteinuria (ACR >100 mg/mmol) Haematuria is present Glomerular filtration rate has worsened rapidly The person is systemically ill.
  • 42. The National Saudi Diabetic Guidelines for PHC • Adults with diabetes and persistent albuminuria (ACR >2. 0 mg/mmol in males, and females) should receive an ACE inhibitor or an ARB to delay progression of CKD, even in the absence of hypertension. • For a person with an abnormal albumin: creatinine ratio, maintain blood pressure below 130/80mmHg.
  • 43. The National Saudi Diabetic Guidelines for PHC Retinopathy • Screening is important for early detection of treatable disease. • Screening intervals for diabetic retinopathy vary according to the individual’s age and type of diabetes. • Tight glycemic, BP, and lipid control reduces the onset and progression of sight-threatening diabetic retinopathy. • Laser therapy reduces the risk of significant visual loss.
  • 44. The National Saudi Diabetic Guidelines for PHC Neuropathy • Screening for distal symmetric polyneuropathy (DPN) starting at diagnosis of type 2 diabetes and 5 years after the diagnosis of type 1 diabetes and at least annually thereafter. • Tests are, monofilament , vibration with 128 tuning fork, and reflexes. • Management of neuropathy include a trial of duloxetine, gabapentin, or pregabalin.
  • 45. The National Saudi Diabetic Guidelines for PHC Erectile Dysfunction • Erectile dysfunction (ED) affects approximately 34 to 45% of men with diabetes. • All adult men with diabetes should be regularly screened for ED with a sexual function history. • The current mainstays of therapy are phosphor diesterase type 5 inhibitors.
  • 46. The National Saudi Diabetic Guidelines for PHC Recommendations: Medical Nutrition Therapy (MNT) • Individuals who have prediabetes or diabetes should receive individualized MNT as needed to achieve treatment goals, preferably provided by a diabetic dietitian.
  • 47. The National Saudi Diabetic Guidelines for PHC Foot care • For all patients with diabetes, perform an annual comprehensive foot examination to identify risk factors predictive of ulcers and amputations – Inspection – Assessment of foot pulses – Test for loss of protective sensation: 10-g monofilament plus testing any one of • Vibration using 128-Hz tuning fork • Pinprick sensation • Ankle reflexes • Vibration perception threshold
  • 48. The National Saudi Diabetic Guidelines for PHC Upper panel • To perform the 10-g monofilament test, place the device perpendicular to the skin, with pressure applied until the monofilament buckles • Hold in place for 1 second and then release Lower panel • The monofilament test should be performed at the highlighted sites while the patient’s eyes are closed
  • 49. The National Saudi Diabetic Guidelines for PHC Foot care • Provide general foot self-care education • Use multidisciplinary approach – Individuals with foot ulcers, high-risk feet; especially prior ulcer or amputation • Refer patients to foot care specialists for ongoing preventive care, life-long surveillance – Smokers – Loss of protective sensation or structural abnormalities – History of prior lower-extremity complications
  • 50. The National Saudi Diabetic Guidelines for PHC • Initial screening for peripheral arterial disease (PAD) – Include a history for claudication, assessment of pedal pulses – Consider obtaining an ankle-brachial index (ABI); many patients with PAD are asymptomatic • Refer patients with significant claudication or a positive ABI for further vascular assessment. – Consider exercise, medications, surgical options.
  • 51. The National Saudi Diabetic Guidelines for PHC In Summary • Diabetes mellitus is a chronic illness that requires continuing medical care and ongoing patient self-management education and support to prevent acute complications and to reduce the risk of long-term complications. • Diabetes care is complex and requires multifactorial risk reduction strategies beyond glycemic control.
  • 52. The National Saudi Diabetic Guidelines for PHC References 1- the Saudi national diabetic guideline for primary care 2014 2-Diabetes mellitus in Saudi Arabia. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ, Khan NB, Al-Khadra A, Al- Marzouki K, Nouh MS, Abdullah M, Attas O, Al-Shahid MS, Al-Mobeireek A. 2004. 3- Diabetes Impact in Saudi Health, Health minister,,Alruba,an et al - initial report 2008 4- Diabetes mellitus type 2 and other chronic non-communicable diseases in the central region, Saudi Arabia (riyadh cohort 2): a decade of an epidemic Nasser M Al-Daghri12*, Omar S Al-Attas12, Majed S Alokail12, Khalid M Alkharfy123, Mansour Yousef4, Shaun Louie Sabico1 and George P Chrousos Al-Daghri et al; licensee BioMed Central Ltd 2011 5- Prevalence of diabetes mellitus in a Saudi community 2011 Khalid A. Alqurashi, Khalid S. Aljabri, and Samia A. Bokhari 6-IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030 Received 19 October 2011; accepted 20 October 2011. published online 14 November 2011
  • 53. The National Saudi Diabetic Guidelines for PHC References 7-Economic costs of diabetes in Saudi Arabia Abdulkarim K. Alhowaish Family Community Med. 2013 Jan-Apr; 20(1): 1–7. 8- Canadian journal of diabetes April 2013 - Volume 37 - Supplement 1 9--Canadian Clinical Practice guidelines 2013 Canadian journal of diabetes; April 2013 - Volume 37 - Supplement 1 10-American Diabetes Association2013 Standards of Medical Care in Diabetes 11- CG66 in NICE clinical guideline 87 September 2010 European Medicines.

Hinweis der Redaktion

  1. In 2012, the International Diabetes Federation (IDF) estimated that 371 million people had diabetes . That number is projected to rise to 552 million (or 1 in 10 adults) by 2030. (IDF Diabetes Atlas) http://www.ncbi.nlm.nih.gov/pubmed/22079683 The IDF ranked Saudi Arabia the sixth of the Top Ten countries of the MENA.
  2. The study of (Diabetes mellitus type 2 and other chronic non-communicable diseases in the central region, Saudi Arabia (Riyadh cohort 2): a decade of an epidemic), 2011, found that, the overall crude prevalence of DMT2 was 23.1%. The age-adjusted prevalence of DMT2 was 31.6%. DMT2 prevalence was significantly higher in males, with an overall age-adjusted prevalence of 34.7%, than in females, who had an overall age-adjusted prevalence of 28.6. The overall crude prevalence of obesity was 31.1% . The age-adjusted prevalence of obesity was 40.0%. The prevalence of obesity was higher in females, with an overall prevalence of 36.5%, than in males (25.1% ). The age-adjusted prevalence of hypertension and CAD were 32.6% and 6.9% . Another study conducted in Jeddah, Armed Force hospital to find the Prevalence of diabetes mellitus in a Saudi community, 2011 found the prevalence of diabetes was 34.1% in males and 27.6% in females. The mean (SD) age for onset of diabetes in males and females was 57.5 and 53.4 (13.1) years, respectively. Females <50 years old had a higher prevalence than males in the corresponding age range—34.1% and 25.1%, respectively (P<.0001). The prevalence of diabetes decreased in patients older than 70 years. The prevalence of body mass index of ≥25 was 72.5%. Among patients with diabetes, the prevalence of body mass index of ≥25 was 85.7% . There was a higher prevalence of obesity (body mass index, ≥25) in females (87.7%) as compared to males (83.1%) Reference : Diabetes Impact in Saudi Health, Health minister,,Alruba,an et al - initial report 2008. Khalid A. Alqurashi, Khalid S. Aljabi, and Samia A. Bokhari
  3. A study Economic costs of diabetes in Saudi Arabia (2013) found that People diagnosed with diabetes, on average, have medical healthcare expenditures that are ten times higher ($3,686 vs. $380) than what expenditures would be in the absence of diabetes. Over 96% of all medical healthcare expenditures attributed to diabetes are incurred by persons of Saudi nationality, with the remaining 4% incurred by persons of non-Saudi nationality. The population age 45-60 incurs 45% of diabetes-attributed costs, with the remaining population under age 15 incurs 3.8%, age 15-44 incurs 27.5%, and age 60 and above incurs 23.8%.(6) Among adults aged 20 to 49 years, those with diabetes were 2 times more likely to see a family physician and 2 to 3 times more likely to see a specialist . Also, people with diabetes were 3 times more likely to require hospital admission in the preceding year with longer lengths of stay . Therefore, the impact of diabetes is significant not only for individuals but also for their families and for society as a whole Reference : Economic costs of diabetes in Saudi Arabia Abdulkarim K. Alhowaish Family Community Med. 2013 Jan-Apr; 20(1): 1–7.
  4. These findings show that the Saudi population can be regarded as a moderate risk population for diabetes mellitus. The present management is unsatisfactory since those who are controlled (HbA1C <7%) are only 20% of diabetic patients. It is suggested that steps must be taken to improve awareness of the disease and to take measures to improve diabetes care Reference : Economic costs of diabetes in Saudi Arabia Abdulkarim K. Alhowaish Family Community Med. 2013 Jan-Apr; 20(1): 1–7.
  5. Diabetes mellitus is a metabolic disorder characterized by the presence of hyperglycemia due to defective insulin secretion, defective insulin action or both References : National Saudi diabetic guidelines 2014 American diabetes standard of care 2013 http://care.diabetesjournals.org/content/36/Supplement_1/S11.full
  6. Diabetes mellitus is classified to three main types and other specific types include a wide variety of relatively uncommon conditions, primarily specific genetically defined forms of diabetes or diabetes associated with other diseases or drug use like treatment of HIV or after organ transplantation. Reference : American diabetes standard of care 2013
  7. HBA1C≥6.5% The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay. OR FPG ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h. OR . Symptoms of hyperglycemia or hyperglycemic crisis, and a casual (random) plasma glucose ≥ 200 mg/dl (11.1 mmol/l). Casual (random) is defined as any time of day without regard to time since last meal. The classic symptoms of hyperglycemia include polyuria, polydipsia, and unexplained weight loss. OR 2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed as described by the World Health Organization using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water. *In the absence of unequivocal hyperglycemia, these criteria should be confirmed by repeated testing. HbA1c >6.5% Reference : American diabetes standard of care 2013
  8. Reference : American diabetes standard of care 2013
  9. These are conditions that place a symptomatic individuals, at risk of developing diabetes and its complications and they would benefit from CV risk factor modification. Reference : American diabetes standard of care 2013
  10. The clinical spectrum of diabetes ranges from a low-risk to a higher-risk individual or to the symptomatic patient who needs immediate treatment. Screening for diabetes implies testing for diabetes in individuals without symptoms who are unaware of their condition. Screening for diabetes will also detect individuals at increased risk for diabetes (prediabetes) or individuals with less severe states of dysglycemia who may still be at risk for type 2 diabetes. Screening strategies vary according to the type of diabetes and evidence of effective interventions to prevent progression of prediabetes to diabetes and/or reduce the risk of complications associated with diabetes.  The growing importance of diabetes screening is undeniable ,to screen for diabetes and prediabetes, the same tests would be used as for diagnosis of both medical conditions.  To be effective, population-based screening would have to involve wide coverage and would have the goal of early identification and subsequent intervention to reduce morbidity and mortality. References : National Saudi diabetic guidelines first update.2014  Canadian Clinical Practice guidelines 2013 Canadian journal of diabetes; April 2013 - Volume 37 - Supplement 1
  11. Preventing type 2 diabetes would result in significant public health benefits, including lower rates of cardiovascular diseases (CVD), renal failure, blindness and premature mortality. Primary approaches to preventing diabetes in a population include the following: 1) programs targeting high-risk individuals in the community (such as those with impaired glucose tolerance [IGT] or obesity) 2) programs targeting high-risk subgroups of the population, such as high-risk ethnic Groups. and 3) programs for the general population, such as those designed to promote physical activity and healthy eating in adults or children References : National Saudi diabetic guidelines first update.2014 Canadian Clinical Practice guidelines 2013  
  12. GLYCATED HEMOGLOBIN TESTING Currently,A1C is the preferred standard for assessing glycemic control. A1C is a reliable estimate of mean plasma glucose (PG) levels and a valuable indicator of treatment effectiveness , over the previous 3 to 4 months for most individuals .and should be measured every 3 months when glycemic targets are not being met and when diabetes therapy is being adjusted. Testing at 6-month intervals may be considered in situations when glycemic targets are consistently achieved . In uncommon circumstances where the rate of red blood cell turnover is significantly shortened or extended (certain anaemias), or the structure of hemoglobin is altered ( haemoglobinpathies),A1C may not accurately reflect glycemic status.  References : National Saudi diabetic guidelines first update.2014  Canadian Clinical Practice guidelines 2013
  13. Reference : Canadian Clinical Practice guidelines 2013 Canadian journal of diabetes; April 2013 - Volume 37 - Supplement 1 There some factors which can affect the accuracy of A1C, and the readings are considered false and cannot taken in consideration.  
  14. Goals should be individualized based on: duration of diabetes age/life expectancy comorbid conditions known CVD or advanced microvascular complications hypoglycemia unawareness Reference: American Diabetes Association2013 Standards of Medical Care in Diabetes 
  15. Optimal glycemic control is fundamental to the management of diabetes. Both fasting and postprandial plasma glucose levels correlate with the risk of complications and contribute to the measured glycated hemoglobin value. When setting treatment goals and strategies, consideration must be given to individual risk factors such as age, prognosis, presence of diabetes complications or comorbidities, and their risk for and ability to perceive hypoglycemia Reference: American Diabetes Association2013 Standards of Medical Care in Diabetes 
  16. References : Canadian Clinical Practice guidelines 2013 Canadian journal of diabetes; April 2013 - Volume 37 - Supplement 1
  17. American Diabetes Association2013 , Standards of Medical Care in Diabetes CG66 in NICE clinical guideline 87 ,September 2010 European Medicines National Saudi diabetic guidelines 2014. Lifestyle modification, including nutritional therapy and physical activity, should continue to be emphasized while pharmacotherapy is being used. As type 2 diabetes is characterized by insulin resistance and ongoing decline in beta cell function, glucose levels will likely worsen over time and treatment must be dynamic. 
  18. A patient-centered approach should be used to guide choice of pharmacological agents; considerations include efficacy, cost, potential side effects, effects on weight, comorbidities, hypoglycemia risk, and patient preferences (E) Due to the progressive nature of type 2 diabetes, insulin therapy is eventually indicated for many patients with type 2 diabetes References: National Saudi diabetic guidelines 2014. American Diabetes Association2013 , Standards of Medical Care in Diabetes  CG66 in NICE clinical guideline 87 ,September 2010 European Medicines
  19. Metformin, if not contraindicated and if tolerated, is the preferred initial pharmacological agent for type 2 diabetes (A) In newly diagnosed type 2 diabetic patients with markedly symptomatic and/or elevated blood glucose levels or A1C, consider insulin therapy, with or without additional agents, from the outset (E) The ADA and EASD have recently partnered on guidance for individualization of use of medication classes and combinations in patients with type 2 diabetes2 This 2012 position statement is less prescriptive than prior algorithms and discusses advantages and disadvantages of the available medication classes and considerations for their use A patient-centered approach is stressed, taking into account patient preferences, cost and potential side effects of each class, effects on body weight, and hypoglycemia risk If noninsulin monotherapy at maximal tolerated dose does not achieve or maintain the A1C target over 3–6 months, add a second oral agent, a GLP-1 receptor agonist, or insulin (A) Reference: National Saudi diabetic guidelines 2014. American Diabetes Association2013 , Standards of Medical Care in Diabetes  CG66 in NICE clinical guideline 87 ,September 2010 European Medicines
  20. When insulin is added to oral antihyperglycemic agents, a single injection of intermediate-acting(NPH) or an extended longacting insulin analogue(insulin glargine or insulin detemir) may be added. This approach may result in better glycemic control with a smaller dose of insulin and may induce less weight gain and less hypoglycemia than that when oral agents are stopped and insulin is used alone . The addition of bedtime insulin to metformin therapy leads to less weight gain than insulin plus a sulfonylurea or twice daily NPH insulin . As type 2 diabetes progresses, doses of basal insulin (intermediate acting or long acting analogues) will need increasing pre-prandial insulin (short acting or rapid acting analogues) may be required. A combination of oral antihyperglycemic agents and insulin often effectively controls glucose levels. References: National Saudi diabetic guidelines 2014. American Diabetes Association2013 , Standards of Medical Care in Diabetes  CG66 in NICE clinical guideline 87 ,September 2010 European Medicines
  21. DPP-4 inhibitors and GLP-1 receptor agonists have been shown to be effective at further lowering glucose levels when combined with insulin therapy. As type 2 diabetes progresses, insulin requirements will likely increase, additional doses of basal insulin (intermediate-acting or long-acting analogues) may need to be added and bolus insulin (short-acting or rapid-acting analogues) may also be required. Insulin regimens based on basal or bolus insulin appear to be equally effective and superior with respect to glycemic lowering compared to biphasic insulin-based regimens References: National Saudi diabetic guidelines 2014. American Diabetes Association2013 , Standards of Medical Care in Diabetes  CG66 in NICE clinical guideline 87 ,September 2010 European Medicines
  22. When other measures no longer achieve or maintain adequate blood glucose control over 3-6 months ,discuss the benefits and risks of insulin therapy. When starting insulin therapy, use a structured programme employing active insulin dose titration that include: Structured education. Frequent self monitoring. Dietary understanding. Management of hypoglycemia. Management of acute changes in plasma glucose control. Support from an appropriately and experienced health care professional References: National Saudi diabetic guidelines 2014. American Diabetes Association2013 , Standards of Medical Care in Diabetes  CG66 in NICE clinical guideline 87 ,September 2010 European Medicines
  23. Begin with human NPH insulin injected at bed-time or twice daily according to need. Consider, as an alternative, using a long-acting insulin analogue (insulin detemir, insulin glargine) if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of a long-acting insulin analogue (insulin detemir, insulin glargine) would reduce the frequency of injections from twice to once daily, or the person's lifestyle is restricted by recurrent symptomatic hypoglycemic episodes, or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs, or the person cannot use the device to inject NPH insulin. References: National Saudi diabetic guidelines 2014. American Diabetes Association2013 , Standards of Medical Care in Diabetes  CG66 in NICE clinical guideline 87 ,September 2010 European Medicines
  24. Consider twice-daily pre-mixed (biphasic) human insulin (particularly if HbA1c ≥ 9.0%). A once-daily regimen may be an option. Consider pre-mixed preparations that include short-acting insulin analogues, rather than pre-mixed preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal, or hypoglycemia is a problem, or blood glucose levels rise markedly after meals Monitor a person on a basal insulin regimen (NPH insulin or a long-acting insulin analogue [insulin detemir, insulin glargine]) for the need for short-acting insulin before meals (or a pre-mixed insulin preparation). Monitor a person who is using pre-mixed insulin once or twice daily for the need for a further injection of short-acting insulin before meals or for a change to a regimen of mealtime plus basal insulin, based on NPH insulin or long acting insulin analogues (insulin detemir, insulin glargine), if blood glucose control remains inadequate References: National Saudi diabetic guidelines 2014. American Diabetes Association2013 , Standards of Medical Care in Diabetes  CG66 in NICE clinical guideline 87 ,September 2010 European Medicines
  25. The following antihyperglycemic agents (listed in alphabetical order), should be considered to lower postprandial blood glucose levels: a)- Alph-glucosidase inhibitor b)- premixed insulin analogues (i.e. biphasic insulin aspart and insulin lispro/protamine) instead of regular /NPH premixtures . c)- meglitinides (repaglinide, nateglinide) instead of sulfonylureas d)- rapid-acting insulin analogues (aspart, gluslisine, lispro) instead of short-acting insulin (i.e. regular insulin). All individuals with type 2 diabetes currently using or starting therapy with insulin or insulin secretagogues should be counseled about the recognition and prevention of drug-induced hypoglycemia References: National Saudi diabetic guidelines 2014. American Diabetes Association2013 , Standards of Medical Care in Diabetes  CG66 in NICE clinical guideline 87 ,September 2010 European Medicines
  26. Reference: National Saudi diabetic guidelines 2014.
  27. Reference: National Saudi diabetic guidelines 2014.
  28. Reference: National Saudi diabetic guidelines 2014.
  29. The first priority in the prevention of macrovascular complications should be reduction of cardiovascular (CV) risk through a comprehensive, multifaceted approach, integrating both lifestyle and pharmacologic measures. Low-dose acetylsalicylic acid therapy may be considered in people with stable CVD. The decision to prescribe antiplatelet therapy for primary prevention of CV events, however, should be based on individual clinical judgment References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013  
  30. Offer low-dose aspirin, (75-162) mg daily, to a person who is (male aged <50 years /female aged <60 years) and has significant other cardiovascular risk factors (features of the metabolic syndrome, strong early family history of cardiovascular disease, smoking, hypertension, extant cardiovascular disease, micro albuminuria) if blood pressure is below 145/90 mmHg Clopidogrel (75mg) should be used instead of aspirin only in those with clear aspirin intolerance. (except in the context of acute cardiovascular events and procedures). *Combination therapy with aspirin(75–162 mg/day) and clopidogrel (75mg/day) is reasonable for up to a year after an acute coronary syndrome. (B)  References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013
  31. Goals of the screening are to improve life expectancy and quality of life by preventing MI and heart failure through the early detection of coronary artery disease (CAD). The majority (65 to 80%) of people with diabetes will die from heart disease . Compared to people without diabetes, people with diabetes (especially women) are at higher risk of developing heart disease, and at an earlier age. A high proportion of deaths occur in patients with no prior signs or symptoms of cardiovascular disease (CVD). Furthermore, people with diabetes have a high prevalence of silent myocardial ischemia, and almost one-third of myocardial infarctions (MIs) occur without recognized or typical symptoms (silent MIs) .  References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013
  32. Goals of the screening are to improve life expectancy and quality of life by preventing MI and heart failure through the early detection of coronary artery disease (CAD). The majority (65 to 80%) of people with diabetes will die from heart disease . Compared to people without diabetes, people with diabetes (especially women) are at higher risk of developing heart disease, and at an earlier age. A high proportion of deaths occur in patients with no prior signs or symptoms of cardiovascular disease (CVD). Furthermore, people with diabetes have a high prevalence of silent myocardial ischemia, and almost one-third of myocardial infarctions (MIs) occur without recognized or typical symptoms (silent MIs) . References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013
  33. Reference: JNC 7
  34. References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013
  35. People with diabetes with hypertension should be treated to a systolic blood pressure goal of 140 mmHg. Lower systolic targets, such as ,130 mmHg, may be appropriate for certain individuals, such as younger patients, if it can be achieved without undue treatment burden. Patients with diabetes should be treated to a diastolic blood pressure,80 mmHg References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013 American Diabetes Association2013 ,Standards of Medical Care in Diabetes
  36. Life style therapy: low sodium , high potassium, DASH diet and Exercise. ACE inhibitors, or ARBS. Multiple-drug therapy (two or more agents at maximal doses) is generally required to achieve blood pressure targets. If ACE inhibitors, ARBs, or diuretics are used, serum creatinine/estimated glomerular filtration rate (eGFR) and serum potassium levels should be monitored Alpha-blockers are not recommended as first-line agents for the treatment of hypertension in persons with diabetes References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013 American Diabetes Association2013 ,Standards of Medical Care in Diabetes
  37. A calcium channel blocker should be the first-line blood pressure-lowering therapy for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant (ACE and ARB are absolute contraindication in pregnancy) For people with diabetes and albuminuria (persistent albumin to creatinine ratio [ACR] ≥ 2. 0 mg/mmol in men and women), an ACE inhibitor or an ARB is recommended as initial therapy. If BP remains ≥ 140/80 mm Hg despite lifestyle interventions and the use of an ACE inhibitor or ARB, additional antihypertensive drugs should be used to obtain target BP. For persons with diabetes and a normal urinary albumin excretion rate, with no chronic kidney disease and with isolated systolic hypertension, a long-acting DHP CCB is an alternative initial choice to an ACE inhibitor, an ARB. or a thiazide-like diuretic References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013 American Diabetes Association2013 ,Standards of Medical Care in Diabetes
  38. The beneficial effects of lowering low-density lipoprotein cholesterol (LDL-C) with statin therapy apply equally well to people with diabetes as to those without the disease  The primary treatment goal for people with diabetes is LDL-C mmol/L(100mg/dl)HDL-c (≥50 mg/dl),TG ≤ 150 mg/dl) which is generally achievable with statin monotherapy  Achievement of the primary goal may require intensification of lifestyle changes and/or statin therapy and, on occasion, the addition of other lipid-lowering medications References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013 American Diabetes Association2013 ,Standards of Medical Care in Diabetes
  39. In adults, screening for CKD in diabetes should be conducted using a random urine ACR and a serum creatinine converted into an eGFR Screening should commence at diagnosis of diabetes in individuals with type 2 diabetes and yearly thereafter, and 5 years after diagnosis in adults with type 1 diabetes and repeated yearly thereafter. A diagnosis of CKD should be made in patients with a random urine ACR >2.0 mg/mmol and/or an eGFR<60 mL/min on at least 2 of 3 samples over a 3-month period. Screening should be delayed when causes of transient albuminuria or low eGFR are present References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013 American Diabetes Association2013 ,Standards of Medical Care in Diabetes
  40. Suspect renal disease, other than diabetic nephropathy and consider further investigation or referral when the albumin: creatinine ratio (ACR) is raised and any of the following apply: there is no significant or progressive retinopathy blood pressure is particularly high or resistant to treatment had a documented normal ACR and develops heavy proteinuria (ACR >100 mg/mmol) significant hematuria is present the glomerular filtration rate has worsened rapidly the person is systemically ill. References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013 American Diabetes Association2013 ,Standards of Medical Care in Diabetes
  41. - People with diabetes on an ACE inhibitor or an ARB should have their serum creatinine and potassium levels checked within 1 to 2 weeks of initiation or titration of therapy. .  Potassium and serum creatinine levels should be checked in people with diabetes receiving an ACE inhibitor or ARB during times of acute illness. .  Level A  Level B The use of Thiazide-like diuretics should be considered in individuals with CKD and diabetes for control of sodium and water retention, hypertension or hyperkalemia . Alternatively, furosemide can be substituted for or added to Thiazide-like diuretics for individuals who fail monotherapy with Thiazide-like diuretics or who have severe sodium and water retention or hyperkalemia. Level C Consideration should be given to stopping ACE inhibitor, ARB and/or diuretic therapy during times of acute illness (E. g. febrile illness, diarrhea), especially when intravascular volume contraction is present or suspected. Women should avoid becoming pregnant when receiving ACE inhibitor or ARB therapy, as the use of medications that has been associated with adverse fetal outcomes.  Level C Adults with diabetes and CKD should be given a “sick day” medication list that outlines which medications should be held during times of acute illness . Level C Combination of agents that block the renin-angiotensin-aldosterone system (ACE inhibitor, ARB, DRI) should not be routinely used in the management of diabetes and CKD . Level A A referral to a nephrologist or internist with an expertise in diabetic nephropathy should be considered if there is a chronic, progressive loss of kidney function, if the eGFR is <30 mL/minute. If the ACR is persistently >60 mg/mmol. Or if the individual is unable to achieve BP targets or remain on renal-protective therapies due to adverse effects, such as hyperkalemia or A >30% increase in serum creatinine within 3 months of starting an ACE inhibitor or RRBs. Level A  References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013 American Diabetes Association2013 ,Standards of Medical Care in Diabetes    
  42. References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013 American Diabetes Association2013 ,Standards of Medical Care in Diabetes
  43. All patients should be screened for distal symmetric polyneuropathy (DPN) starting at diagnosis of type 2 diabetes and 5 years after the diagnosis of type 1 diabetes and at least annually thereafter, using simple clinical tests; Monofilament , vibration with 128 tuning fork, and reflexes. Management of neuropathy include a trial of duloxetine, gabapentin, or pregabalin References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013 American Diabetes Association2013 ,Standards of Medical Care in Diabetes
  44. Erectile dysfunction (ED) affects approximately 34 to 45% of men with diabetes, has been demonstrated to negatively impact quality of life among those affected across all age strata, and may be the earliest sign of cardiovascular disease. All adult men with diabetes should be regularly screened for ED with a sexual function history. The current mainstays of therapy are phosphor diesterase type 5 inhibitors. They have been reported to have a major impact on erectile function and quality of life, and should be offered as first-line therapy to men with diabetes wishing treatment for ED References: National Saudi diabetic guidelines 2014 Canadian Clinical Practice guidelines 2013 American Diabetes Association2013 ,Standards of Medical Care in Diabetes
  45. The general recommendations for medical nutrition therapy (MNT)1 are included on this slide Individuals who have prediabetes or diabetes should receive individualized MNT as needed to achieve treatment goals, preferably provided by a registered dietitian familiar with the components of diabetes MNT (A) Because it can result in cost savings and improved outcomes (B), MNT should be covered by insurance and other payers (E) Although numerous studies have attempted to identify the optimal mix of macronutrients for meal plans of people with diabetes, it is unlikely that one such combination of macronutrients exists; the best mix of carbohydrates, protein, and fat appears to vary depending on individual circumstances MNT is an integral component of diabetes prevention, management, and self-management education In addition to its role in preventing and controlling diabetes, ADA recognizes the importance of nutrition as an essential component of an overall healthy lifestyle A full review of the evidence regarding nutrition in preventing and controlling diabetes and its complications and additional nutrition-related recommendations can be found in the ADA position statement “Nutrition Recommendations and Interventions for Diabetes,”2 which is being updated as of 2013 References: National Saudi diabetic guidelines 2014 American Diabetes Association2013 ,Standards of Medical Care in Diabetes
  46. Recommendations for foot care in patients with diabetes are summarized in four slides For all patients with diabetes, perform an annual comprehensive foot examination to identify risk factors predictive of ulcers and amputations The foot examination should include inspection, assessment of foot pulses, and testing for loss of protective sensation (LOPS) (10-g monofilament plus testing any one of: vibration using 128-Hz tuning fork, pinprick sensation, ankle reflexes, or vibration perception threshold) (B) Amputation and foot ulceration, consequences of diabetic neuropathy and/or peripheral artery disease (PAD), are common and major causes of morbidity and disability in people with diabetes; early recognition and management of risk factors can prevent or delay adverse outcomes Risk of ulcers or amputations is increased in people who have the following risk factors: Previous amputation Past foot ulcer history Peripheral neuropathy Foot deformity Peripheral vascular disease Visual impairment Diabetic nephropathy (especially patients on dialysis) Poor glycemic control Cigarette smoking
  47. Recommendations for foot care in patients with diabetes are summarized in four slides This slide illustrates how to perform the 10-g monofilament test2 References: National Saudi diabetic guidelines 2014 American Diabetes Association2013 ,Standards of Medical Care in Diabetes
  48. Recommendations for foot care in patients with diabetes are summarized in four slides Provide general foot self-care education to all patients with diabetes (B) A multidisciplinary approach is recommended for individuals with foot ulcers and high-risk feet, especially those with a history of prior ulcer or amputation (B) Refer patients who smoke, have LOPS and structural abnormalities, or have history of prior lower-extremity complications to foot care specialists for ongoing preventive care and life-long surveillance (C) References: National Saudi diabetic guidelines 2014 American Diabetes Association2013 ,Standards of Medical Care in Diabetes
  49. Recommendations for foot care in patients with diabetes are summarized in four slides Initial screening for peripheral arterial disease (PAD) should include a history for claudication and an assessment of the pedal pulses; consider obtaining an ankle-brachial index (ABI), as many patients with PAD are asymptomatic (C) Refer patients with significant claudication or a positive ABI for further vascular assessment and consider exercise, medications, and surgical options (C) Initial screening for PAD should include a history for claudication and an assessment of the pedal pulses A diagnostic ABI should be performed in any patient with symptoms of PAD Due to the high estimated prevalence of PAD in patients with diabetes and the fact that many patients with PAD are asymptomatic, an ADA consensus statement on PAD (386) suggested that a screening ABI be performed in patients over 50 years of age and be considered in patients under 50 years of age who have other PAD risk factors (e.g., smoking, hypertension, hyperlipidemia, or duration of diabetes >10 years) Refer patients with significant symptoms or a positive ABI for further vascular assessment and consider exercise, medications, and surgical options References: National Saudi diabetic guidelines 2014 American Diabetes Association2013 ,Standards of Medical Care in Diabetes